Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks
Eli Lilly announced positive Phase 3 trial results for its EBGLYSS dermatitis treatment and its retatrutide obesity and diabetes drug.
Share
Why It Matters
Eli Lilly's new weight loss medicine worked well in a long test. This shows the company is making progress on a medicine many people need.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.